Scaffold hopping from synthetic RXR modulators by virtual screening and de novo design.
暂无分享,去创建一个
Gisbert Schneider | Francesca Grisoni | Lukas Friedrich | Daniel Merk | G. Schneider | F. Grisoni | D. Merk | Elena Gelzinyte | Lukas Friedrich | E. Gelžinytė
[1] Anton Simeonov,et al. Firefly luciferase in chemical biology: a compendium of inhibitors, mechanistic evaluation of chemotypes, and suggested use as a reporter. , 2012, Chemistry & biology.
[2] P. Chambon,et al. Retinoid X receptor gamma signaling accelerates CNS remyelination , 2011, Nature Neuroscience.
[3] H. Kakuta,et al. Retinoid X receptor ligands: a patent review (2007 – 2013) , 2014, Expert opinion on therapeutic patents.
[4] Ewgenij Proschak,et al. Nonacidic Farnesoid X Receptor Modulators. , 2017, Journal of medicinal chemistry.
[5] A. D. de Lera,et al. Natural and Structure-based RXR Ligand Scaffolds and Their Functions. , 2017, Current Topics in Medicinal Chemistry.
[6] G. Thatcher,et al. Rexinoids as Therapeutics for Alzheimer's Disease: Role of APOE. , 2017, Current topics in medicinal chemistry.
[7] Gerd Geisslinger,et al. A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase To Counter Nonalcoholic Steatohepatitis. , 2017, Journal of medicinal chemistry.
[8] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[9] Lucia Altucci,et al. Design of selective nuclear receptor modulators: RAR and RXR as a case study , 2007, Nature Reviews Drug Discovery.
[10] Markus Hartenfeller,et al. DOGS: Reaction-Driven de novo Design of Bioactive Compounds , 2012, PLoS Comput. Biol..
[11] Ewgenij Proschak,et al. Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery. , 2017, Journal of medicinal chemistry.
[12] Gregor Eichele,et al. International Union of Pharmacology. LXIII. Retinoid X Receptors , 2006, Pharmacological Reviews.
[13] M. Berciano,et al. Relaunching an old drug: the potential role of bexarotene in neurodegenerative diseases , 2016, Journal of Neurology.
[14] Petra Schneider,et al. Scaffold Hopping by “Fuzzy” Pharmacophores and its Application to RNA Targets , 2007, Chembiochem : a European journal of chemical biology.
[15] G. Schneider,et al. Scaffold‐Hopping Potential of Ligand‐Based Similarity Concepts , 2006, ChemMedChem.
[16] Gisbert Schneider,et al. Flashback Forward: Reaction-Driven De Novo Design of Bioactive Compounds , 2013 .
[17] Petra Schneider,et al. Chemically Advanced Template Search (CATS) for Scaffold-Hopping and Prospective Target Prediction for ‘Orphan’ Molecules , 2013, Molecular informatics.
[18] G. Bemis,et al. The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.
[19] A. D. de Lera,et al. An Endogenous Mammalian Retinoid X Receptor Ligand, At Last! , 2016, ChemMedChem.
[20] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[21] Petra Schneider,et al. Identifying the macromolecular targets of de novo-designed chemical entities through self-organizing map consensus , 2014, Proceedings of the National Academy of Sciences.
[22] Igor V. Tetko,et al. Application of Associative Neural Networks for Prediction of Lipophilicity in ALOGPS 2.1 Program , 2002, J. Chem. Inf. Comput. Sci..
[23] L Zhang,et al. Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids. , 1994, Journal of medicinal chemistry.